India Sees First Significant Decline In Drug Sales Growth
This article was originally published in PharmAsia News
Executive Summary
The growth rate of India's generics drug industry fell to just 3.6 percent during the year ending in September, down from 11.4 percent the previous year. IMS Health research company attributed the reduced growth rate to increased competition and a need to reduce costs during that period. Some of the decline could be due to a decline in U.S. sales, which fell by 2.7 percent in September even though the volume of generics grew by 5.4 percent. The United States buys about half of India's overall drug exports, valued at $7 billion. IMS called 2008 the first significant decline in sales growth in the pharma industry. (Click here for more
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.